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ABSTRACT
Contrast-induced nephropathy (CIN) affects in-hospital, short- and long-term morbidity and mortality. It also leads to pro-
longed hospital stay and increased medical cost. Given the potential clinical severity of CIN, there has been considerable in-
terest in the development of preventative strategies to reduce the risk of contrast-induced renal deterioration in at-risk popul-
ations. A number of pharmacologic and mechanical preventive measures have been attempted, but no method other than 
adequate periprocedural hydration has been conclusively successful. Since its introduction in 2000, N-acetylcysteine (NAC) 
has been widely investigated, albeit with conflicting findings for its nephroprotection capability in patients receiving contrast 
media procedures. However, there is still virtually no definitive evidence of effectiveness of NAC. Although the exact mecha-
nism responsible for the protective action of NAC from renal function deterioration remains unclear, the antioxidant and vas-
odilatory properties of NAC have been suggested as the main mechanisms. This review summarizes the current status of NAC 
as a potential agent to prevent renal functional deterioration and its limitations. (Korean Circ J 2011;41:695-702)
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Introduction
Contrast-induced nephropathy (CIN) is usually defined as 
an acute decline in renal function, expressed as a relative incre-
ase in serum creatinine (SCr) concentration of at least 25% or 
an absolute increase in SCr of 0.5 mg/dL (44.2 µmol/L) in the 
absence of other etiologies.
1) CIN is a significant problem in 
clinical practice, but also one that is often unrecognized. In 
12% of cases, it is the third leading cause of hospital-acquired 
acute renal failure
2) and is associated with 36% mortality in 
patients who require in-hospital dialysis with 19% survival at 
2 years.
3)4) When there are no risk factors, the incidence of CIN 
is low (<5%).
5) In modern clinical practice, the characteristic 
demographic change is a growing elderly population, often 
patients with cardiovascular and renal comorbidities. Such a 
change is associated with a greater number of contrast-enhanc-
ed invasive diagnostic and interventional coronary proce-
dures, which increases the likelihood of further renal deteri-
oration due to radiocontrast.
6)7) In view of the high morbidity 
and mortality associated with CIN, measures taken to prevent 
or minimize its occurrence in patients at-risk are extremely im-
portant. 
Intravascular volume expansion with saline or sodium bi-
carbonate and low- or iso-osmolar contrast agents, such as 
iodixanol, are all associated with a decreased rate of CIN.
8) Al-
though low- or iso-osmolar contrast agents with adequate hy-
dration reduces the risk for CIN by two-thirds, they did not to-
tally eliminate the risk.
9) Therefore, many clinical trials have 
evaluated various pharmacological agents and periproce-
dural factors in an effort to identify successful strategies for 
reducing the risk.
10-14) Pharmacological agents evaluated for 
their potential role in reducing CIN risk include vasodilators 
and antioxidants, a reflection of the current understanding of 
the pathophysiology of contrast-induced renal injury. Vaso-
dilatory intervention with dopamine,
15) fenoldopam,
16) calcium 
channel blockers,
17) and theophylline
18) have been investigat-
ed, but results are inconsistent, calling for additional large, 
prospective, randomized studies. 
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one of the antioxidants that has been investigated extensively 
as an agent for CIN prevention.
19)20) Tepel and colleagues re-
ported in 2000 an almost 90% relative risk reduction in the in-
cidence of CIN in patients with chronic kidney disease (CKD) 
given NAC added to prophylactic hydration after intravenous 
administration of contrast media for elective computed tomo-
graphy examinations. Moreover, greater efficacy was found 
with increased NAC dosing (1,200 mg vs. 600 mg, twice dai-
ly),
21) consistent with the suggestion that the antioxidant ef-
fects of NAC are dose-dependent.
22) These findings provided 
the rationale to investigate use of NAC for prevention of CIN 
in patients with CKD undergoing cardiovascular procedures 
and receiving intra-arterial contrast agents.
However, despite these positive findings, the true efficacy 
of NAC for CIN prevention remains unclear given several dis-
cordant meta-analyses, mainly as a result of a high degree of 
heterogeneity among trials.
23-29) 
Although not having been consistently shown to be effec-
tive,
30-32) NAC is often recommended and used in an effort to 
reduce the rate of CIN due to its ease in administration, easy 
availability, low cost, and few side effects.
33)34) 
This review focuses on the current status of NAC and in-
tends to guide to renal protection in patients receiving contrast 
procedures. 
N-Acetylcysteine as an Antioxidant-
Evidence From Experimental Research
Although there have been a number of in-vivo studies and 
in vitro animal studies, which have the potential to be extrap-
olated to humans, the pathogenesis of CIN in humans is still 
unclear. 
The main mechanisms of CIN are suggested as a direct re-
nal tubular toxicity and renal medullary ischemia.
35) Adminis-
tration of contrast medium increases the production of neph-
rotoxic oxygen free radicals.
36)37) There is a large body of evid-
ence that reactive oxygen species have a role in the renal da-
mage caused by radio-contrast agents. 
38-40) 
NAC is an antioxidant that attenuates ischemic renal fail-
ure in animal studies.
41)42) Besides scavenging oxygen free radi-
cals that mediate cell necrosis after myocardial infarction
43) 
and after angioplasty,
44) NAC may act as an antioxidant to in-
hibit ischemic cell death in the kidney. 
Antioxidants such NAC and ascorbic acid protect tubule 
cells from apoptosis related to reactive oxygen species.
45) The 
cytotoxicity of contrast media (CM) on human embryonic ki-
dney (HEK 293), porcine proximal renal tubular (LLC-PK1), 
and canine Madin-Darby distal tubular renal (MDCK) cells 
has been evaluated, and the effectiveness of various antioxi-
dant compounds like NAC, ascorbic acid, and sodium bicar-
bonate in preventing CM cytotoxicity has been studied. Both 
low- and iso-osmolar CM induce a dose-dependent renal cell 
apoptosis. NAC and ascorbic acid, but not sodium bicarbon-
ate, prevents this CM-induced apoptosis.
In a similar study comparing three antioxidants (NAC, as-
corbic acid, and probucol), NAC pretreatment significantly im-
proved HEK cell viability as compared with control (p<0.001). 
Probucol or ascorbic acid pretreatment does not show re-
duction of cell death caused by CM.
46) This result may indi-
cate that NAC is a better antioxidant than ascorbic acid with 
regard to the CIN prevention.
47) The comparison of NAC with 
ascorbic acid is important, because the combination of these 
two measures has no additive effect in reducing CIN rate as 
compared with use of NAC alone.
48) This may be mainly attri-
buted to their shared similar mechanism of oxygen free rad-
ical scavenging. 
A recently published large animal study
50) also supports the 
benefit of NAC in CIN prevention. In the study, intracoro-
nary radiographic CM combined with NAC protected renal 
function and reduced myocardial infarction size in a pig mo-
del of ischemia and reperfusion. Histopathologic analysis of 
the myocardium revealed a reduction in programmed cell 
death by NAC-enhanced contrast medium that may explain 
the increase in ischemia tolerance. NAC-enhanced contrast me-
dium administration blunted the rise in SCr levels by 60% 
and decreased renal tubule cell apoptosis.
Contrast media also reduce renal function by altering renal 
hemodynamics as well and NAC has the potential to prevent 
CIN by improving this. Reduced blood flow in the renal outer 
medulla, which has a high demand for oxygen and is very vul-
nerable to hypoxia, might result from increased perivascular 
hydrostatic pressure, high viscosity, or changes in vasoactive 
substances such as nitric oxide, adenosine, and endothelin 
by contrast dye.
49)50) 
In addition to the CM injected, volume depletion has been 
recognized as a predisposing factor for CIN. In a study,
52) sa-
line or high-osmolar CM was injected into volume-depleted 
rats and the glomerular filtration rate (GFR) and renal plas-
ma flow rate were measured 24 hours later. Both rates were re-
duced by 50% in contrast-injected rats, as compared with sa-
line-injected, water depleted rats. CM did not induce renal 
dysfunction and enhance lipid peroxidation in non-water de-
pleted rats. However in water depleted contrast-treated rats, 
specific products of membrane lipid peroxidation, namely ph-
osphatidylcholine and phosphatidylethanolamine hydroper-
oxide, which are markers of oxidative stress, were more than 
two-fold higher than saline-treated water depleted rats. Th-
erefore, the contrast medium appeared to induce oxidant-
mediated injury only in water depleted rats.
51) 
Some studies have suggested that NAC has vasodilatory pro-
perties. In one study with 14 dogs, NAC (150 mg/kg, follow-
ed by a 20 mg/kg/hr infusion) increased blood flow in mes-
enteric, renal and especially femoral arteries than control gr-
oup.
52) Oxygen delivery and oxygen-uptake were higher in Sang-Ho Jo   697
the NAC-treated dogs than in the control animals. Moreover, 
NAC ameliorated ischemia in kidney by general properties as 
an antioxidant or a possible interaction with NAC and NO.
53)
Mitogen activated protein kinases (MAPKs) are integral 
components of the parallel MAPK cascades activated in re-
sponse to a variety of cellular stress inducing ischemia/ATP 
depletion and inflammatory cytokines. Members of the MA-
PK family, in particular c-Jun N-terminal kinase (JNK), are 
activated in the kidney following ischemia/reperfusion. Pre-
treatment with a combination of NAC with sodium nitropr-
usside and phosphoramidon can completely inhibit MAPK.
54) 
NAC has also been reported to block the expression of vas-
cular-cell adhesion molecule 1 and the activation of nuclear 
factor-κB in glomerular mesangial cells,
55) which implies 
that NAC may protect kidney function by blocking a signal 
in the pathogenesis of glomerular mesangial cell disorders.
 
Clinical Evidence of N-Acetylcysteine
The first human study with respect to kidney function dealt 
with hepatic failure from drug poisoning. Early administra-
tion of NAC prevented a reduction in renal function in pa-
tients with acetaminophen poisoning who had liver failure, 
and NAC may have improved renal function in patients with 
the hepatorenal syndrome.
56-59) 
A small clinical study dealing examining NAC in the pre-
vention of CIN was published in 2000.
60) The investigators 
enrolled 83 patients with chronic renal failure (mean SCr, 2.4 
mg/dL) who were undergoing computed tomography. NAC 
(600 mg, orally, twice daily before and after CM) was admin-
istered with concomitant saline hydration. CIN occurred 10-times 
less, 2% in the NAC group and 21% in the control group {p= 
0.01, relative risk, 0.1; 95% confidence interval (0.02-0.9)}. The 
publication of these results spurred a myriad of clinical trial, 
which produced mixed data, even in a meta-analysis.
Patients with acute myocardial infarction treated with pri-
mary percutaneous coronary intervention (PCI) are at higher 
risk of CIN than those undergoing elective PCI.
61) In patients 
with acute myocardial infarction, several conditions may con-
tribute to the development of renal dysfunction. Impaired sys-
temic perfusion due to depressed left ventricular function, a 
larger dose of contrast medium, and the impossibility of start-
ing renal prophylaxis before exposure to contrast medium may 
be involved. 
The first study evaluating the effect of NAC on CIN in the 
setting of primary PCI in patient with ST elevation of myo-
cardial infarction was published in 2006. One hundred and 
sixteen patients were randomized to receive NAC (600 mg 
intravenous bolus before CAG and 600 mg orally twice 48 
hours after primary PCI), 119 were randomized to receive a 
double dose of NAC (1,200 mg, same schedule) and 119 were 
randomized to placebo. SCr increase ≥25% was regarded as 
confirmation of the development of CIN.
62) CIN occurred in 
a dose responsive manner, with 5% in the double dose NAC 
group, 15% in the usual dose group, and 33% in the placebo 
group (p<0.001) (Fig. 1). In-hospital mortality was higher in 
patients with CIN than those without it (26% vs. 1%, p<0.002). 
Moreover, the rate for the composite end point of death, acute 
renal failure requiring temporary renal-replacement therapy, 
or the need for mechanical ventilation was significantly low-
er in the double and usual dose NAC groups than placebo, in 
a dose-dependent manner (5 %, 7%, and 17% in the three gr-
oups, respectively; p=0.002).
Recently contradictory study results have been published in 
the same clinical setting with a use of only intravenous NAC 
in patients with ST-segment elevation myocardial infarction 
undergoing primary PCI. Activated oxygen protein prod-
ucts and oxidized low-density lipoprotein as markers for ox-
idative stress were measured with an administration of NAC 
and placebo. These markers were reduced by as much as 20% 
in the NAC group (intravenous bolus of 1,200 mg before PCI 
and 1,200 mg intravenously twice daily for the 48 hours after 
PCI) (p<0.05), whereas no change was detected in the pla-
cebo group. However, the data did not indicate an additional 
clinical benefit to placebo with respect to CIN. The primary 
end point, CIN, occurred in 14% of the NAC group and 20% 
of the placebo group (p=0.28).
63) 
Another study also demonstrated negative results with in-
travenous NAC. In the study, 398 acute coronary syndrome 
patients were randomized to receive an intravenous double 
dose of NAC (n=205; 1,200 mg bolus followed by 200 mg/hr 
for 24 hours) and placebo (n=192). There was no difference 
for the primary end point of CIN defined as an increase in 
Fig. 1. Linear trends for low rate of contrast-induced nephropathy 
by dose of NAC and by normal and reduced creatinine clearance 
rates (>60 mL/min and ≤60 mL/min, respectively). The p values 
refer to comparisons among the placebo group, the group receiv-
ing a standard dose of NAC, and the group receiving a double 
dose of NAC (calculated with the use of chi-square for trend). No 
significant interactions were found between groups and creatinine 
clearance (p=0.25).
73) NAC: N-acetylcysteine, CCr: creatinine clear-
ance rate.
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SCr concentration ≥25% above the baseline level within 72 
hours of the administration of IV contrast CIN in 16% of the 
NAC group and in 13% of the placebo group (p=0.40). Recent 
small-scale studies showed similar negative results.
65) 
The discrepancy of results may reflect a low contrast dose 
and, for the negative results, somewhat preserved renal func-
tion. Therefore, it is premature to recommend the strategy of 
intravenous NAC or oral NAC followed by intravenous NAC 
in primary angioplasty until more definitive data emerges. 
Some investigators have argued that NAC influences SCr, 
the surrogate marker of GFR, without affecting true GFR per 
se. In an uncontrolled study of healthy volunteers, NAC re-
duced SCr, but not cystatin C, prompting the conclusion that 
NAC might affect SCr independent of the GFR.
66) However, 
this effect of NAC has not been investigated in the setting of 
renal insufficiency. Some contradictory results have been re-
ported. One study that assayed both SCr and cystatin C re-
ported a significant correlation between the parameters at 
baseline and a stronger correlation 48 hours after contrast ex-
posure in the NAC treatment group.
67) Similarly, in random-
ized trials designed to prevent acute renal deterioration in 
subjects with renal insufficiency that used peri-operative 
high-dose NAC infusion (300 mg/kg intravenously), SCr and 
cystatin C demonstrated concordant response. There was 
same pattern of creatinine-lowering effect, urinary creatinine 
excretion and plasma creatinine/plasma cyctatin C ratio for 
the NAC and placebo groups.
68)69) Therefore, it is unlikely that 
NAC reduced the SCr independent of renal function. It must 
be noted that the SCr level is an imperfect surrogate outcome 
measure for nephropathy, and that protection against neph-
ropathy based on altered SCr level has not been confirmed 
using other measures.
Clinical Researches Not Favoring 
N-Acetylcysteine Use 
in Preventing Renal Failure
In a recent large, multicenter, randomized clinical trial in-
cluding 2,308 patients, coronary angiography was perform-
ed in patients with at least one risk factor of CIN (70 years of 
age, renal failure, diabetes mellitus, full term for HF, hyper-
tension). Patients were allocated to NAC (1,200 mg orally 
twice daily) before and after the contrast procedure. NAC did 
not reduce CIN or clinical outcomes. CIN occurred at a same 
rate, 12.7%, in NAC and placebo groups. Clinical outcomes 
of mortality or need for dialysis at 30 days was 2.2% and 2.3% 
in the NAC and placebo group, respectively, with hazard ra-
tio of 0.97 {95% confidence interval (CI), 0.56-1.69; p=0.92} 
(Table 3).
70) In subgroups categorized by basal renal function, 
contrast dose, age, and diabetes status, there were no differ-
ences with respect to CIN rate and cardiovascular events be-
tween the NAC and placebo groups.
It is the largest randomized relevant clinical trial performed 
to date, and was well designed and well conducted. Moreover 
Table 1. Recommendations for prevention of contrast-induced nephropathy
72)
Intervention Dose Class* Level†
All patients with CKD
OMT (including statins, β-blockers, and ACE
  inhibitors or sartans) is recommended.
According to clinical indications. I A
Hydration with isotonic saline is 
  recommended.
1 mL/kg/h.
12 hours before and continued for 24 hours after 
  the procedure (0.5 mL/kg/h if EF <35% or NYHA >2).
I A
N-Acetylcysteine administration may be 
  considered.
600-1,200 mg. 24 hours before and continued 
  for 24 hours after the procedure.
IIb A
Infusion of sodium bicarbonate 0.84% may be
  considered.
1 hour before: bolus=body weight in kg×0.462 mEq.
i.v. infusion for 6 hours after the procedure
  =body weight in kg×0.154 mEq per hour.
IIb A
Patients with mild, moderate, or severe CKD
Use of LOCM or IOCM is recommended. <350 mL or <4 mL/kg I‡ A‡
Patients with severe CKD
Prophylactic haemofiltration 6 hours before 
  complex PCI should be considered.
Fluid replacement rate 1,000 mL/h without weight
  loss and saline gydration, continued for 24 hours 
  after the procedure.
IIa B
Elective haemodialysis is not recommended 
  as a preventive measure.
III B
*Class of recommendation, †Level of evidence, ‡Recommendation pertains to the type of contrast. CKD: chronic kidney disease, OMT: opti-
mal medical therapy, ACE: angiotensin-converting enzyme, EF: ejection fraction, NYHA: New York Heart Association, LOCM: low osmolar 
contrast media, IOCM: iso-osmolar contrast media, i.v.: intravenous, PCI: percutaneous coronary interventionSang-Ho Jo   699
its statistical power and analysis bring confidence to the re-
sults. Considering that the previous conflicting results of small 
trials and some meta-analyses were rooted in the study het-
erogeneity and publication bias, where negative results are less 
likely to be published, this multicenter prospective randomiz-
ed clinical trial is of great interest and significance. Some ex-
pert expressed that this trial will influence clinical practice by 
dissuading use of NAC for the purpose of renal protection.
71)
In light of this latest trial, NAC may well fall out of favor as 
a routine treatment option until new evidence from studies 
involving longer duration of use and much higher doses are 
published. In the interim, a recommendation is to adequately 
expand intravascular volume with saline at least 12 hours be-
fore and after the contrast procedure (Table 1 and 2). 
Mixed Results From Some  
Meta-Analysis
Several meta-analyses were conducted to resolve difficult 
issue of true effectiveness of NAC. However, the results have 
been disappointingly equivocal, given the limitations of the 
small studies on which the analyses were are based. 
In 2003, a meta-analysis including seven trials involving 
805 patients demonstrated that administration of NAC and hy-
dration significantly reduced the relative risk of contrast ne-
phropathy by 56% {0.435 (95% CI 0.215-0.879), p=0.02} as 
compared with periprocedural hydration alone in patients 
with chronic renal insufficiency. However, significant hetero-
geneity was indicated (overall CIN incidence in NAC group, 2- 
26%). Other meta-analyses confirmed the heterogeneity in 
these trials related to publication bias, dose of the agent, co-
hort studied, and definition of outcome. 
Dose may matter. In a recent meta-analysis that included 
16 trials involving 1,677 high-risk patients with renal insuffi-
ciency using higher NAC doses, a 64% decrease in the likeli-
hood of acute renal failure was evident. This study demonst-
rated no heterogeneity and no evidence of publication bias 
(p=0.34). Most studies of NAC’s prophylactic potential have 
used lower doses (e.g., 600 mg twice a day), raising the pos-
sibility that the failure to consistently see a benefit may have re-
sulted from under-dosing. 
Identified patient and study characteristics may be respon-
Table 2. Recommendations of interventions commonly used to reduce the risk of contrast-induced nephropathy
74)
Intervention Details Evidence Comments Recommendation
Interavenous 
  saline therapy
Intravenous 0.9% saline 
  at 1mL/kg/hr for 24 hours, 
  beginning 2-12 hours before 
  administration of contrast 
  medium
Several small randomized 
  trials that compared 
  intraveous saline with oral
  fluids lone, shorter regimens 
  of intravenous fluid, 
  or 0.45% saline
Optimal duration 
  of intravenous therapy 
  not fully established 
  by existing trials
Generally 
  recommended
Contrast medium
Type Low osmolality Meta-analysis of several 
  randomized controlled trials 
  comparing low-osmolar with 
  high-osmolar contrast 
  mediums
Futher data on the relative 
  nephrotoxicity of iso-osmlar
  contrast mediums are 
  required.
Low-osmolality 
  mediums 
  recommended
Dose Lowest required to complete 
  the procedure
Cohort sudies that associate 
  higher doses with greater risk
A dose >5 mL×kg of body 
  weight÷serum creatinine 
  level in mg/dL associated 
  with higher risk
Lowest dose possible
  recommended
Intravenous 
  sodium 
  bicarbonate
Intravenous sodium 
  bicarbonate 154 mmol/L 
  at 3 mL/kg/hr before 
  administration of contrast 
  medium, then 1 mL/kg/hr 
  for 6 hours after 
  administration
A single randomized controlled 
  trial that suggested a lower 
  risk of an increase of >25% 
  in creatinine levels with 
  bicarbonate as compared 
  with 0.9% saline given 
  at the same rate of infusion 
  and duration
Methodologic flaws 
  in the tral
Not generally 
  recommended unless
  efficacy confirmed 
  by further trials
N-acetylcysteine Most commonly, 600 mg 
  by mouth every 12 hours 
  for four doses, beginning 
  before administration 
  of contrast medium
Multiple randomized trials 
  and meta-analyses
Inconsistent trial results 
  for unknown reasons: 
  optimal dose not clear
Not generally 
  recommended 
  pending further data 
  to confirm efficacy700   Acetylcysteine and Contrast-Induced Nephropathy
sible for some, but not all, of this inconsistency. So, at present, 
a definitive conclusion cannot be made.
 
Conclusions
There have been mixed data on whether prophylactic oral 
and IV NAC administration reduces the incidence of CIN in 
small trials and even in meta-analyses, although its use is gen-
erally recommended, given its low cost, easy availability, and 
favorable side effect profile. Moreover, evidence of any im-
provement in clinical outcomes at long-term follow-up is still 
lacking, despite beneficial effects in CIN prevention.
Research on NAC and the incidence of CIN is too inconsis-
tent at present to warrant a conclusion on efficacy or a recom-
mendation for its routine use. A large, randomized, placebo-
controlled trial, a pooled analysis of patient-level data, or both 
may resolve this issue.
The efficacy of NAC for preventing CIN remains unprov-
en. Future studies should not be based on a primary end point 
of changed SCr level. Instead, the efficacy and safety of NAC 
should be sought in critically ill patients at risk for CIN. 
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